[[1, [[[50.0, 57.0, 124, 11], "\u00d6zg\u00fcn \u00c7al\u0131\u015fma/Original Article"], [[211.0, 59.0, 211, 10], "Mikrobiyol Bul 2020;54(4):547-558/doi: 10.5578/mb.70087"], [[172.0, 75.0, 237, 8], "Geli\u015f Tarihi (Received): 02.08.2020 \u2022 Kabul Edili\u015f Tarihi (Accepted): 28.09.2020"], [[83.0, 101.0, 287, 20], "Piperasilin/Tazobaktam ve Siprofloksasin"], [[70.0, 119.0, 312, 18], "Sub-minimal \u0130nhibit\u00f6r Konsantrasyonlar\u0131nda"], [[53.0, 137.0, 344, 20], "Pseudomonas aeruginosa Biyofilm Olu\u015fumunun ve"], [[82.0, 155.0, 287, 18], "Quorum Sensing Genlerinin Ara\u015ft\u0131r\u0131lmas\u0131"], [[57.0, 200.0, 337, 16], "Investigation of Pseudomonas aeruginosa Biofilm Formation"], [[54.0, 216.0, 342, 16], "and Quorum Sensing Genes in Piperacillin/Tazobactam and"], [[74.0, 231.0, 303, 16], "Ciprofloxacin Sub-minimal Inhibitory Concentrations"], [[43.0, 269.0, 348, 13], "Berna ERDAL1(ID), Meltem YALINAY2(ID), \u00c7i\u011fdem ELMAS3(ID), G\u00fclce Naz YAZICI4(ID)"], [[43.0, 281.0, 288, 12], "1 Tekirda\u011f Nam\u0131k Kemal \u00dcniversitesi T\u0131p Fak\u00fcltesi, T\u0131bbi Mikrobiyoloji Anabilim Dal\u0131, Tekirda\u011f."], [[43.0, 289.0, 326, 12], "1 Tekirdag Nam\u0131k Kemal University Faculty of Medicine, Department of Medical Microbiology, Tekirdag, Turkey."], [[43.0, 300.0, 226, 12], "2 Gazi \u00dcniversitesi T\u0131p Fak\u00fcltesi, T\u0131bbi Mikrobiyoloji Anabilim Dal\u0131, Ankara."], [[43.0, 308.0, 268, 12], "2 Gazi University Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey."], [[43.0, 319.0, 238, 12], "3 Gazi \u00dcniversitesi T\u0131p Fak\u00fcltesi, Histoloji ve Embriyoloji Anabilim Dal\u0131, Ankara."], [[43.0, 327.0, 282, 12], "3 Gazi University Faculty of Medicine, Department of Histology and Embryology, Ankara, Turkey."], [[43.0, 338.0, 299, 12], "4 Erzincan Binali Y\u0131ld\u0131r\u0131m \u00dcniversitesi T\u0131p Fak\u00fcltesi, Histoloji ve Embriyoloji Anabilim Dal\u0131, Erzincan."], [[43.0, 346.0, 339, 12], "4 Erzincan Binali Yildirim University Faculty of Medicine, Department of Histology and Embryology, Erzincan, Turkey."], [[43.0, 369.0, 361, 8], "* Bu \u00e7al\u0131\u015fma, birinci yazar\u0131n \u201cAntimikrobiyallerin subinhibit\u00f6r konsantrasyonlar\u0131n\u0131n Pseudomonas aeruginosa vir\u00fclans\u0131 \u00fcze-"], [[47.0, 377.0, 358, 8], "rine etkilerinin molek\u00fcler d\u00fczeyde incelenmesi, 2013\u201d ba\u015fl\u0131kl\u0131 Gazi \u00dcniversitesi Sa\u011fl\u0131k Bilimleri Enstit\u00fcs\u00fc T\u0131bbi Mikrobiyoloji"], [[47.0, 385.0, 101, 8], "Program\u0131 Doktora tez \u00e7al\u0131\u015fmas\u0131d\u0131r."], [[43.0, 405.0, 356, 8], "Makale At\u0131f\u0131: Erdal B, Yal\u0131nay M, Elmas \u00c7, Yaz\u0131c\u0131 GN. Piperasilin/tazobaktam ve siprofloksasin sub-minimal inhibit\u00f6r kon-"], [[43.0, 413.0, 365, 8], "santrasyonlar\u0131nda Pseudomonas aeruginosa biyofilm olu\u015fumunun ve quorum sensing genlerinin ara\u015ft\u0131r\u0131lmas\u0131. Mikrobiyol Bul"], [[43.0, 422.0, 65, 8], "2020;54(4):547-558."], [[43.0, 451.0, 11, 10], "\u00d6Z"], [[54.0, 466.0, 349, 10], "Pseudomonas aeruginosa, do\u011fada yayg\u0131n olarak bulunan, nonfermentatif, oksidaz testi pozitif, hare-"], [[43.0, 476.0, 368, 10], "ketli gram-negatif bir basildir. Minimal \u00fcreme ko\u015fullar\u0131nda \u00fcreyebilmesi, do\u011fada yayg\u0131n olarak bulunma-"], [[43.0, 486.0, 359, 10], "s\u0131, biyofilm olu\u015fturma yetene\u011fi gibi vir\u00fclans fakt\u00f6rlerinin olmas\u0131 ve birden fazla antibiyoti\u011fe geli\u015ftirdi\u011fi"], [[43.0, 496.0, 368, 10], "diren\u00e7 mekanizmalar\u0131 P.aeruginosa\u2019y\u0131 olduk\u00e7a \u00f6nemli bir bakteri haline getirmektedir. Biyofilm olu\u015fturma"], [[43.0, 506.0, 365, 10], "yetenekleri, etken olduklar\u0131 hastal\u0131klar\u0131n semptomlar\u0131n\u0131n daha \u015fiddetli seyretmesine ve tedavi g\u00fc\u00e7l\u00fc\u011f\u00fcne"], [[43.0, 516.0, 372, 10], "neden olmaktad\u0131r. Bu \u00e7al\u0131\u015fmada, P.aeruginosa enfeksiyonlar\u0131n\u0131n tedavisinde kullan\u0131lan piperasilin/tazobak-"], [[43.0, 526.0, 366, 10], "tam (TZP) ve siprofloksasin (CIP) antibiyotiklerinin sub-minimal inhibit\u00f6r konsantrasyonlar\u0131n\u0131n (sub-M\u0130K)"], [[43.0, 536.0, 361, 10], "P.aeruginosa\u2019n\u0131n biyofilm yap\u0131m\u0131 \u00fczerine etkilerinin ve biyofilm olu\u015fum \u015fiddeti ile quorum sensing (QS)"], [[43.0, 546.0, 371, 10], "genleri aras\u0131ndaki ili\u015fkinin ara\u015ft\u0131r\u0131lmas\u0131 ama\u00e7lanm\u0131\u015ft\u0131r. \u00c7al\u0131\u015fmaya, Gazi \u00dcniversitesi T\u0131p Fak\u00fcltesi T\u0131bbi Mik-"], [[43.0, 556.0, 362, 10], "robiyoloji Laboratuvar\u0131 k\u00fclt\u00fcr koleksiyonunda bulunan 24 P.aeruginosa izolat\u0131 dahil edilmi\u015ftir. Her izolat"], [[43.0, 566.0, 365, 10], "i\u00e7in TZP ve CIP antibiyotiklerinin M\u0130K de\u011ferleri mikrodil\u00fcsyon y\u00f6ntemi ile tespit edilmi\u015ftir. Antibiyotiksiz"], [[43.0, 576.0, 360, 10], "ortamda ve antibiyotiklerin sub-M\u0130K (M\u0130K/2, M\u0130K/4 ve M\u0130K/8) konsantrasyonlar\u0131ndaki biyofilm tabaka-"], [[43.0, 586.0, 352, 10], "s\u0131 taramal\u0131 elektron mikroskobu (SEM) ile g\u00f6r\u00fcnt\u00fclenmi\u015ftir. Biyofilm \u00f6zellikleri belirlenmi\u015f 24 izolat\u0131n"], [[48.0, 616.0, 361, 8], "\u0130leti\u015fim (Correspondence): Dr. \u00d6\u011fr. \u00dcyesi Berna Erdal, Tekirda\u011f Nam\u0131k Kemal \u00dcniversitesi T\u0131p Fak\u00fcltesi, T\u0131bbi Mikrobiyoloji"], [[102.0, 624.0, 306, 8], "Anabilim Dal\u0131, Tekirda\u011f, T\u00fcrkiye. Tel (Phone): +90 282 250 5586, E-posta (E-mail): berdal@nku.edu.tr"]], [680, 453]], [10, [[[43.0, 41.0, 254, 8], "Piperasilin/Tazobaktam ve Siprofloksasin Sub-minimal \u0130nhibit\u00f6r Konsantrasyonlar\u0131nda"], [[43.0, 50.0, 271, 8], "Pseudomonas aeruginosa Biyofilm Olu\u015fumunun ve Quorum Sensing Genlerinin Ara\u015ft\u0131r\u0131lmas\u0131"], [[43.0, 70.0, 337, 13], "tur22. Bu \u00e7al\u0131\u015fmada ise CIP ve TZP\u2019nin sub-M\u0130K\u2019lerde, P.aeruginosa\u2019n\u0131n biyofilm olu\u015fu-"], [[43.0, 85.0, 349, 11], "munu anlaml\u0131 olarak azaltt\u0131\u011f\u0131 ve bu azalt\u0131c\u0131 etkinin doza ba\u011f\u0131ml\u0131 oldu\u011fu tespit edilmi\u015ftir."], [[43.0, 98.0, 338, 11], "Sub-M\u0130K\u2019lerde en belirgin azalma M\u0130K/2 de\u011ferinde belirlenmi\u015ftir. Bu durum, biyofilm"], [[43.0, 111.0, 353, 11], "olu\u015fumu \u00fczerine her iki antibiyoti\u011fin de ayn\u0131 oranda etki etti\u011fi sonucunu g\u00f6stermektedir."], [[54.0, 129.0, 327, 11], "Literat\u00fcrdeki \u00e7al\u0131\u015fmalara bak\u0131ld\u0131\u011f\u0131nda, enfeksiyon hastal\u0131klar\u0131n\u0131n do\u011fru tedavisinde;"], [[43.0, 142.0, 340, 11], "uygun ajan\u0131n se\u00e7imi kadar en etkili dozun saptanmas\u0131n\u0131n da \u00f6nem arz etti\u011fi sonucuna"], [[43.0, 153.0, 70, 13], "var\u0131lmaktad\u0131r20-22."], [[54.0, 174.0, 339, 11], "Bu \u00e7al\u0131\u015fman\u0131n sonu\u00e7lar\u0131, sub-M\u0130K\u2019lerde kinolon grubu antibiyotiklerden CIP\u2019nin ve be-"], [[43.0, 187.0, 348, 11], "ta-laktam/beta-laktamaz inhibit\u00f6r kombinasyonlar\u0131ndan olan TZP\u2019nin biyofilm geli\u015fimini"], [[43.0, 200.0, 346, 11], "azaltt\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. Buna g\u00f6re, CIP ve TZP\u2019nin P.aeruginosa kaynakl\u0131 biyofilm en-"], [[43.0, 213.0, 310, 11], "feksiyonlar\u0131n\u0131n tedavisinde iyi bir tercih olabilece\u011fi sonucuna var\u0131labilmektedir."], [[54.0, 232.0, 326, 11], "Geli\u015fen teknolojiyle beraber, deneysel biyofilm \u00e7al\u0131\u015fmalar\u0131nda kullan\u0131lan y\u00f6ntemle-"], [[43.0, 245.0, 336, 11], "rin say\u0131s\u0131 da artmaktad\u0131r. Her ge\u00e7en y\u0131l geni\u015f bir ara\u015ft\u0131rmac\u0131 kitlesi, farkl\u0131 g\u00f6r\u00fcnt\u00fcleme"], [[43.0, 258.0, 330, 11], "y\u00f6ntemlerini kullanarak, P.aeruginosa tedavisinde kullan\u0131lan antimikrobiyallerin sub-"], [[43.0, 269.0, 314, 13], "M\u0130K\u2019lerinde biyofilm yap\u0131s\u0131nda meydana gelen de\u011fi\u015fiklikleri ara\u015ft\u0131rmaktad\u0131r20,21."], [[54.0, 289.0, 338, 11], "Yap\u0131lan bir \u00e7al\u0131\u015fmada, seftazidimin M\u0130K/4 konsantrasyonu ile P.aeruginosa PAO1 stan-"], [[43.0, 302.0, 358, 11], "dart su\u015funun 48 saat ink\u00fcbasyonu sonunda biyofilm yap\u0131m\u0131ndaki azalma konfokal lazer ta-"], [[43.0, 314.0, 356, 13], "rama mikroskobu kullan\u0131larak belirlenmi\u015ftir20. Bu \u00e7al\u0131\u015fmada, biyofilm olu\u015fumunun en fazla"], [[43.0, 328.0, 347, 11], "her iki antibiyoti\u011fin M\u0130K/2 konsantrasyonlar\u0131nda azald\u0131\u011f\u0131 SEM kullan\u0131larak g\u00f6sterilmi\u015ftir."], [[54.0, 347.0, 337, 11], "Bakteri pop\u00fclasyonunun QS mekanizmas\u0131 arac\u0131l\u0131\u011f\u0131 ile bir koordinasyon i\u00e7inde davran-"], [[43.0, 360.0, 353, 11], "d\u0131\u011f\u0131 d\u00fc\u015f\u00fcn\u00fclmektedir. Biyofilm olu\u015fumu da dahil olmak \u00fczere bakteriyel patojeniteyi des-"], [[43.0, 373.0, 350, 11], "tekleyen vir\u00fclans fakt\u00f6rlerinin ekspresyonunu d\u00fczenleyen sistemlerin aras\u0131nda QS \u00f6nemli"], [[43.0, 384.0, 90, 13], "bir rol oynamaktad\u0131r12."], [[54.0, 405.0, 314, 11], "2018 y\u0131l\u0131nda bir grup ara\u015ft\u0131rmac\u0131 taraf\u0131ndan farkl\u0131 klinik \u00f6rneklerden izole edilen"], [[43.0, 418.0, 351, 11], "P.aeruginosa izolatlar\u0131n\u0131n biyofilm yap\u0131m\u0131 ve ili\u015fkili QS genlerinin varl\u0131\u011f\u0131n\u0131n ara\u015ft\u0131r\u0131ld\u0131\u011f\u0131 bir"], [[43.0, 431.0, 350, 11], "\u00e7al\u0131\u015fmada, izolatlar\u0131n %77.5\u2019inin biyofilm olu\u015fturdu\u011fu ve bu izolatlar\u0131n %100\u2019\u00fcnde lasR,"], [[43.0, 444.0, 352, 11], "rhlI ve rhlR genleri tespit edilirken, %97.5\u2019inde lasI geni saptanm\u0131\u015ft\u0131r. Biyofilm olu\u015fturma-"], [[43.0, 457.0, 346, 11], "yan dokuz izolatta t\u00fcm genlerin varl\u0131\u011f\u0131 g\u00f6sterilmi\u015ftir. Biyofilm \u00fcretmeyen dokuz izolat\u0131n"], [[43.0, 470.0, 334, 11], "\u00fc\u00e7\u00fcnde bu genlerle ilgili amplikonlar sekanslanm\u0131\u015f ve standart biyofilm \u00fcreten PAO1"], [[43.0, 483.0, 341, 11], "su\u015fu ile kar\u015f\u0131la\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r. Sonu\u00e7ta, lasR proteininin sekanslanmas\u0131 s\u0131ras\u0131nda valin amino"], [[43.0, 494.0, 344, 13], "asidinin eklenmesine neden olan \u00fc\u00e7 n\u00fckleotidin (T, C ve G) insersiyonu g\u00f6sterilmi\u015ftir12."], [[43.0, 509.0, 346, 11], "Bu \u00e7al\u0131\u015fma sonucunda; zay\u0131f, orta kuvvetli ve kuvvetli biyofilm olu\u015fturan t\u00fcm izolatlarda"], [[43.0, 522.0, 344, 11], "(n= 24) rhlI geni tespit edilmi\u015ftir. Bu sonuca ba\u011fl\u0131 olarak rhlI geninin biyofilm olu\u015fumu-"], [[43.0, 535.0, 342, 11], "nun her a\u015famas\u0131nda \u00f6nemli bir rol ald\u0131\u011f\u0131 s\u00f6ylenebilir. Orta kuvvetli ve kuvvetli biyofilm"], [[43.0, 548.0, 349, 11], "olu\u015fturan izolatlar\u0131n tamam\u0131nda (n= 19) lasI/lasR genlerinin saptanm\u0131\u015f olmas\u0131 ayr\u0131ca dik-"], [[43.0, 561.0, 336, 11], "kat \u00e7ekici bir sonu\u00e7tur. Bu sonu\u00e7, olgun biyofilm yap\u0131s\u0131n\u0131n olu\u015fmas\u0131nda las sisteminin"], [[43.0, 574.0, 347, 11], "gereklili\u011fini destekler nitelikte g\u00f6r\u00fcnmektedir. RhlR geninin baz\u0131 izolatlarda g\u00f6sterileme-"], [[43.0, 587.0, 348, 11], "mesi; rhlR gen b\u00f6lgesi i\u00e7in tasarlanm\u0131\u015f primerlerin, primer ba\u011flanma b\u00f6lgesindeki nokta"], [[43.0, 600.0, 338, 11], "mutasyon, baz kayb\u0131 gibi nedenlerle ba\u011flanamamas\u0131 sonucu amplifikasyonun ger\u00e7ek-"], [[43.0, 628.0, 16, 10], "556"], [[317.0, 628.0, 92, 10], "M\u0130KROB\u0130YOLOJ\u0130 B\u00dcLTEN\u0130"]], [680, 453]], [11, [[[299.0, 44.0, 113, 8], "Erdal B, Yal\u0131nay M, Elmas \u00c7, Yaz\u0131c\u0131 GN."], [[42.0, 71.0, 341, 11], "le\u015femedi\u011fi \u015feklinde yorumlanabilir. Bu izolatlardaki mutasyon varl\u0131\u011f\u0131n\u0131n ileri molek\u00fcler"], [[42.0, 84.0, 263, 11], "incelemelerle ayd\u0131nlat\u0131lmas\u0131n\u0131n yararl\u0131 olaca\u011f\u0131 sonucuna var\u0131lm\u0131\u015ft\u0131r."], [[53.0, 102.0, 336, 11], "Sonu\u00e7 olarak; CIP ve TZP gibi P.aeruginosa\u2019ya y\u00f6nelik antimikrobiyallerin doz aral\u0131kla-"], [[42.0, 115.0, 344, 11], "r\u0131n\u0131n tekrar de\u011ferlendirilmesinin klinik uygulamalarda \u00f6nemli olaca\u011f\u0131 d\u00fc\u015f\u00fcn\u00fclmektedir."], [[42.0, 128.0, 339, 11], "Klinik izolat say\u0131s\u0131n\u0131n az olmas\u0131 ve izolatlar\u0131n \u00f6zel bir hasta grubuna ait olmamas\u0131 \u00e7al\u0131\u015f-"], [[42.0, 141.0, 345, 11], "man\u0131n k\u0131s\u0131tlay\u0131c\u0131 yanlar\u0131d\u0131r. Bu nedenle, antimikrobiyallerin sub-M\u0130K\u2019lerinin P.aeruginosa"], [[42.0, 154.0, 346, 11], "enfeksiyonlar\u0131n\u0131n tedavi s\u00fcrecine olan katk\u0131lar\u0131 hakk\u0131nda yeterli bilgi sa\u011flayabilmek ama-"], [[42.0, 167.0, 352, 11], "c\u0131yla sonu\u00e7lar\u0131m\u0131z\u0131n, daha fazla say\u0131da izolat\u0131n dahil edildi\u011fi geni\u015f \u00f6l\u00e7ekli \u00e7al\u0131\u015fmalarla des-"], [[42.0, 180.0, 344, 11], "teklenmesi gerekmektedir. Ayr\u0131ca biyofilmde \u00f6nemli rol ald\u0131\u011f\u0131 d\u00fc\u015f\u00fcn\u00fclen QS sisteminin"], [[42.0, 193.0, 340, 11], "molek\u00fcler y\u00f6ntemlerle ara\u015ft\u0131r\u0131lmas\u0131n\u0131n etkin tedavi yakla\u015f\u0131m\u0131n\u0131n planlanmas\u0131 a\u00e7\u0131s\u0131ndan"], [[42.0, 206.0, 341, 11], "son derece \u00f6nemli olaca\u011f\u0131 kan\u0131s\u0131na var\u0131lm\u0131\u015ft\u0131r. P.aeruginosa vir\u00fclans fakt\u00f6rlerinin hangi"], [[42.0, 219.0, 347, 11], "mekanizmalarla d\u00fczenlendi\u011fi ile ilgili bilgilerimizin artmas\u0131, tedavide yeni gen hedefleri-"], [[42.0, 232.0, 312, 11], "nin belirlenmesini, tedavi stratejilerini ve ba\u015far\u0131s\u0131n\u0131 olumlu y\u00f6nde etkileyecektir."], [[42.0, 251.0, 82, 11], "ET\u0130K KURUL ONAYI"], [[53.0, 270.0, 232, 11], "Bu \u00e7al\u0131\u015fma i\u00e7in etik kurul onay\u0131na gerek bulunmamaktad\u0131r."], [[42.0, 288.0, 76, 11], "\u00c7IKAR \u00c7ATI\u015eMASI"], [[53.0, 307.0, 287, 11], "Yazarlar bu makale ile ilgili herhangi bir \u00e7\u0131kar \u00e7at\u0131\u015fmas\u0131 bildirmemi\u015flerdir."], [[56.0, 334.0, 53, 11], "KAYNAKLAR"], [[42.0, 351.0, 315, 8], "1. Lee K, Yoon SS. Pseudomonas aeruginosa biofilm, a programmed bacterial life for fitness. J Microbiol"], [[56.0, 361.0, 104, 8], "Biotechnol 2017; 27(6): 1053-64."], [[42.0, 374.0, 340, 8], "2. Rehman A, Patrick WM, Lamont IL. Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new"], [[56.0, 384.0, 207, 8], "approaches to an old problem. J Med Microbiol 2019; 68(1): 1-10."], [[42.0, 397.0, 335, 8], "3. Aykan \u015eB, \u00c7iftci \u0130H. Meta-Analiz: T\u00fcrkiye\u2019de Pseudomonas aeruginosa izolatlar\u0131n\u0131n son 11 y\u0131ldaki antibiyotik"], [[56.0, 407.0, 163, 8], "diren\u00e7 de\u011fi\u015fimi. Mikrobiyol Bul 2015; 49(3): 352-65."], [[42.0, 420.0, 341, 8], "4. Goel N, Bhambhwani V, Ghosh B. Multidrug-resistant Pseudomonas aeruginosa endophthalmitis in a silicone"], [[56.0, 430.0, 325, 8], "oil-filled eye treated with piperacillin/tazobactam: report of a case and review of literature. Int Ophtalmol"], [[56.0, 440.0, 70, 8], "2015; 35(4): 599-602."], [[42.0, 453.0, 340, 8], "5. P\u00e9rez-P\u00e9rez M, Jorge P, Rodr\u00edguez PG, Pereira MO, Louren\u00e7o L . Quorum sensing inhibition in Pseudomonas"], [[56.0, 463.0, 283, 8], "aeruginosa biofilms: new insights through network mining. Biofouling 2017; 33(2): 128-42."], [[42.0, 475.0, 326, 8], "6. Nicholas MM, Brahmchetna B, Ruxana TS. Pseudomonas aeruginosa biofilms: host response and clinical"], [[56.0, 485.0, 240, 8], "implications in lung infections. Am J Respir Cell Mol Biol 2018; 58(4): 428-39."], [[42.0, 498.0, 310, 8], "7. Clinical and Laboratory Standards Institute (CLSI). M100, Performance standards for antimicrobial"], [[56.0, 508.0, 148, 8], "susceptibility testing. 2017. 27th ed. Wayne, PA"], [[42.0, 521.0, 331, 8], "8. Qu L, She P, Wang Y, Liu F, Zhang D, Chen L, et al. Effects of norspermidine on Pseudomonas aeruginosa"], [[56.0, 531.0, 230, 8], "biofilm formation and eradication. MicrobiologyOpen 2016; 5(3): 402-12."], [[42.0, 544.0, 327, 8], "9. Schaber JA, Carty NL, McDonald NA, Graham ED, Cheluvappa R, Griswold JA, et al. Analysis of quorum"], [[56.0, 554.0, 314, 8], "sensing-deficient clinical isolates of Pseudomonas aeruginosa. J Med Microbiol 2004; 53(Pt 9): 841-53."], [[42.0, 567.0, 345, 8], "10. Senturk S, Ulusoy S, Bosgelmez-Tinaz G, Yagc\u0131 A. Quorum sensing and virulence of Pseudomonas aeruginosa"], [[56.0, 577.0, 214, 8], "during urinary tract infections. J Infect Dev Ctries 2012; 6(06): 501-7."], [[42.0, 590.0, 346, 8], "11. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms"], [[56.0, 600.0, 233, 8], "and alternative therapeutic strategies. Biotechnol Adv 2019; 37(1): 177-92."], [[43.0, 628.0, 92, 10], "M\u0130KROB\u0130YOLOJ\u0130 B\u00dcLTEN\u0130"], [[392.0, 628.0, 16, 10], "557"]], [680, 453]], [12, [[[43.0, 41.0, 254, 8], "Piperasilin/Tazobaktam ve Siprofloksasin Sub-minimal \u0130nhibit\u00f6r Konsantrasyonlar\u0131nda"], [[43.0, 50.0, 271, 8], "Pseudomonas aeruginosa Biyofilm Olu\u015fumunun ve Quorum Sensing Genlerinin Ara\u015ft\u0131r\u0131lmas\u0131"], [[42.0, 71.0, 347, 8], "12. Lima JLC, Alves LR, Jacom\u00e9 PRLA, Neto JPB, Maciel MAV, Morais MMC. Biofilm production by clinical isolates"], [[56.0, 81.0, 328, 8], "of Pseudomonas aeruginosa and structural changes in LasR protein of isolates non biofilm-producing. Braz J"], [[56.0, 91.0, 96, 8], "Infect Dis 2018; 22(2): 129-36."], [[42.0, 103.0, 330, 8], "13. Lima JLC, Alves LR, Paz JNPD, Rabelo MA, Maciel MAV, Morais MMC. Analysis of biofilm production by"], [[56.0, 113.0, 333, 8], "clinical isolates of Pseudomonas aeruginosa from patients with ventilator-associated pneumonia. Rev Bras Ter"], [[56.0, 123.0, 91, 8], "Intensiva 2017; 29(3): 310-6."], [[42.0, 136.0, 349, 8], "14. Pokharel K, Dawadi BR, Bhatt CP, Gupte S. Prevalence of Pseudomonas aeruginosa and its antibiotic sensitivity"], [[56.0, 146.0, 173, 8], "pattern. J Nepal Health Res Counc 2019; 17(1): 109-13."], [[42.0, 159.0, 337, 8], "15. Abuhussain SSA, Sutherland CA, Nicolau DP. Single \u03b2-lactams versus combinations as empiric therapy for"], [[56.0, 169.0, 324, 8], "infections with Pseudomonas aeruginosa: assessing the in vitro susceptibility. Infect Dis 2020; 52(1): 33-8."], [[42.0, 182.0, 350, 8], "16. Barrio-Tofi\u00f1o ED, L\u00f3pez-Causap\u00e9 C, Cabot G, Rivera A, Benito N, Segura C, et al. Genomics and susceptibility"], [[56.0, 192.0, 309, 8], "profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain. Antimicrob Agents"], [[56.0, 202.0, 118, 8], "Chemother 2017; 61(11): e01589-17."], [[42.0, 215.0, 320, 8], "17. Davis R, Brown PD. Multiple antibiotic resistance index, fitness and virulence potential in respiratory"], [[56.0, 225.0, 239, 8], "Pseudomonas aeruginosa from Jamaica. J Med Microbiol 2016; 65(4): 261-71."], [[42.0, 238.0, 303, 8], "18. Karake\u00e7e E, Terzi HA, \u00c7ift\u00e7i \u0130H. Pseudomonas aeruginosa izolatlar\u0131n\u0131n antibiyotik duyarl\u0131l\u0131klar\u0131n\u0131n"], [[56.0, 248.0, 164, 8], "de\u011ferlendirmesi. Medeniyet Med J 2014; 29(1): 20-3"], [[42.0, 260.0, 341, 8], "19. Cepas V, L\u00f3pez Y, Mu\u00f1oz E, Rolo D, Ardanuy C, Mart\u0131 S, et al. Relationship between biofilm formation and"], [[56.0, 270.0, 276, 8], "antimicrobial resistance in gram-negative bacteria. Microb Drug Resist 2019; 25(1): 72-9."], [[42.0, 283.0, 351, 8], "20. Otani S, Hiramatsu K, Hashinaga K, Komiya K, Umeki K, Kishi K, et al. Sub-minimum inhibitory concentrations"], [[56.0, 293.0, 328, 8], "of ceftazidime inhibit Pseudomonas aeruginosa biofilm formation. J Infect Chemother 2018; 24(6): 428-33."], [[42.0, 306.0, 342, 8], "21. Gupta P, Chhibber S, Harjai K. Subinhibitory concentration of ciprofloxacin targets quorum sensing system"], [[56.0, 316.0, 325, 8], "of Pseudomonas aeruginosa causing inhibition of biofilm formation & reduction of virulence. Indian J Med"], [[56.0, 326.0, 82, 8], "Res 2016; 143(5): 643-51."], [[42.0, 339.0, 348, 8], "22. Fonseca AP, Sousa JC. Effect of antibiotic-induced morphological changes on surface properties, motility and"], [[56.0, 349.0, 335, 8], "adhesion of nosocomial Pseudomonas aeruginosa strains under different physiological states. J Appl Microbiol"], [[56.0, 359.0, 74, 8], "2007; 103(5): 1828-37."], [[43.0, 628.0, 16, 10], "558"], [[317.0, 628.0, 92, 10], "M\u0130KROB\u0130YOLOJ\u0130 B\u00dcLTEN\u0130"]], [680, 453]], [2, [[[43.0, 41.0, 254, 8], "Piperasilin/Tazobaktam ve Siprofloksasin Sub-minimal \u0130nhibit\u00f6r Konsantrasyonlar\u0131nda"], [[43.0, 50.0, 271, 8], "Pseudomonas aeruginosa Biyofilm Olu\u015fumunun ve Quorum Sensing Genlerinin Ara\u015ft\u0131r\u0131lmas\u0131"], [[43.0, 72.0, 357, 10], "QS genleri (lasI, lasR, rhlI ve rhlR) polimeraz zincir reaksiyonu (PCR) y\u00f6ntemi ile kromozomal DNA\u2019n\u0131n"], [[43.0, 82.0, 360, 10], "amplifikasyonu yap\u0131larak tespit edilmi\u015ftir. \u00c7al\u0131\u015fma sonucunda, iki antibiyoti\u011fin de sub-M\u0130K konsantras-"], [[43.0, 92.0, 362, 10], "yonlar\u0131nda, antibiyotiksiz durum ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, biyofilm yap\u0131m\u0131n\u0131 doz ba\u011f\u0131ml\u0131 olarak azaltt\u0131\u011f\u0131 ve"], [[43.0, 102.0, 358, 10], "en fazla biyofilm olu\u015fumunun azald\u0131\u011f\u0131 konsantrasyonun M\u0130K/2 oldu\u011fu tespit edilmi\u015ftir. Elde edilen bu"], [[43.0, 112.0, 357, 10], "sonu\u00e7lar, SEM g\u00f6r\u00fcnt\u00fclerine bak\u0131larak da do\u011frulanm\u0131\u015ft\u0131r. \u00c7al\u0131\u015fmada; orta kuvvetli ve kuvvetli biyofilm"], [[43.0, 122.0, 369, 10], "olu\u015fturan toplam 19 izolatta lasI, lasR ve rhlI genleri tespit edilirken, rhlR geni, kuvvetli biyofilm olu\u015fturan"], [[43.0, 132.0, 354, 10], "izolatlar\u0131n alt\u0131s\u0131nda, orta kuvvetli biyofilm olu\u015fturan izolatlar\u0131n d\u00f6rd\u00fcnde, zay\u0131f biyofilm olu\u015fturan izo-"], [[43.0, 142.0, 362, 10], "latlar\u0131n ise \u00fc\u00e7\u00fcnde tespit edilmi\u015ftir. P.aeruginosa enfeksiyonlar\u0131n\u0131n tedavisinde kullan\u0131lan antibiyotiklerin"], [[43.0, 152.0, 370, 10], "sub-M\u0130K konsantrasyonlar\u0131n\u0131n P.aeruginosa\u2019n\u0131n biyofilm yap\u0131m\u0131 \u00fczerine etkilerinin ara\u015ft\u0131r\u0131lmas\u0131 ve biyofilm"], [[43.0, 162.0, 368, 10], "yap\u0131m\u0131 ile ili\u015fkili QS sistemlerinin ara\u015ft\u0131r\u0131larak daha iyi anla\u015f\u0131lmas\u0131 yeni tedavi yakla\u015f\u0131mlar\u0131n\u0131n bulunmas\u0131na"], [[43.0, 172.0, 366, 10], "olanak sa\u011flayacak ve y\u00fcksek morbidite ve mortaliteye sahip enfeksiyonlarla m\u00fccadelede farkl\u0131 se\u00e7enekler"], [[43.0, 182.0, 50, 10], "sunabilecektir."], [[54.0, 197.0, 328, 10], "Anahtar kelimeler: Antimikrobiyal; biyofilm; Pseudomonas aeruginosa; sub-M\u0130K; quorum sensing."], [[43.0, 213.0, 40, 10], "ABSTRACT"], [[54.0, 229.0, 346, 10], "Pseudomonas aeruginosa is a non-fermentative, oxidase-positive, motile gram-negative bacillus wi-"], [[43.0, 239.0, 356, 10], "despread in nature. The virulence factors of P.aeruginosa including the ability to grow under minimal"], [[43.0, 249.0, 373, 10], "growth conditions, the widespread presence in nature, and the ability to form biofilms make P.aeruginosa"], [[43.0, 259.0, 366, 10], "a highly important bacterium along with its resistance mechanisms against many antibiotics. The ability"], [[43.0, 269.0, 370, 10], "to form biofilms increases the symptom severity in diseases caused by P.aeruginosa and causes difficulties"], [[43.0, 279.0, 350, 10], "in the treatment. The aim of this study was to investigate the effects of sub-minimal inhibitory con-"], [[43.0, 289.0, 358, 10], "centrations (sub-MIC) of piperacillin/tazobactam (TZP) and ciprofloxacin (CIP) which are used for the"], [[43.0, 299.0, 371, 10], "treatment of P.aeruginosa infections on biofilm formation and to investigate the relationship between the"], [[43.0, 309.0, 369, 10], "severity of biofilm formation and Quorum Sensing (QS) genes. The study included 24 P.aeruginosa isola-"], [[43.0, 319.0, 373, 10], "tes from the culture collection of Medical Microbiology Laboratory of Gazi University Faculty of Medicine."], [[43.0, 329.0, 367, 10], "MIC values of TZP and CIP antibiotics were determined by the microdilution method. The biofilm layers"], [[43.0, 339.0, 370, 10], "in the antibiotic-free medium and in the sub-MIC (MIC/2, MIC/4 ve MIC/8) concentrations of antibiotics"], [[43.0, 349.0, 364, 10], "were visualized by using a scanning electron microscope (SEM). The QS genes (lasI, lasR, rhlI, and rhlR)"], [[43.0, 359.0, 371, 10], "of the 24 isolates with known biofilm characteristics were identified via the amplification of chromosomal"], [[43.0, 369.0, 358, 10], "DNA by using PCR method. In the study, it was foundthat both antibiotics reduced biofilm formation"], [[43.0, 379.0, 363, 10], "in a dose-dependent manner in sub-MIC concentrations compared to the antibiotic-free condition and"], [[43.0, 389.0, 370, 10], "that MIC/2 was the concentration, which reduced the biofilm formation most. These results were further"], [[43.0, 399.0, 360, 10], "confirmed by viewing the SEM images. The QS genes lasI, lasR, and rhlI were detected in a total of 19"], [[43.0, 409.0, 359, 10], "isolates with moderately strong and strong biofilm formation, the rhlR gene was detected in six of the"], [[43.0, 419.0, 359, 10], "strong biofilm-forming isolates, in four of the moderately strong biofilm-forming isolates, and in three"], [[43.0, 429.0, 360, 10], "of the weak biofilm-forming isolates, respectively. The investigation of the effects of sub-MIC concent-"], [[43.0, 439.0, 361, 10], "rations of antimicrobials, used for the treatment of P.aeruginosa infections, on the biofilm formation of"], [[43.0, 449.0, 362, 10], "P.aeruginosa and the investigation and better understanding of the QS systems associated with biofilm"], [[43.0, 459.0, 370, 10], "production will allow for finding out new treatment approaches and offer different options in combating"], [[43.0, 469.0, 159, 10], "infections with high morbidity and mortality."], [[54.0, 484.0, 293, 10], "Keywords: Antimicrobial; biofilm; Pseudomonas aeruginosa; sub-MIC; quorum sensing."], [[43.0, 511.0, 23, 11], "G\u0130R\u0130\u015e"], [[54.0, 529.0, 348, 11], "Pseudomonas aeruginosa, imm\u00fcn yetmezli\u011fi olan, uzun s\u00fcre kemoterapi veya radyotera-"], [[43.0, 542.0, 362, 11], "pi alan, metabolik veya malign hastal\u0131\u011f\u0131 olan bireylerde, ya\u015fl\u0131larda, a\u011f\u0131r yan\u0131kl\u0131 ki\u015filerde akut"], [[43.0, 555.0, 357, 11], "ve kronik enfeksiyonlara neden olan f\u0131rsat\u00e7\u0131 bir patojendir. \u00d6zellikle hastane enfeksiyonlar\u0131-"], [[43.0, 566.0, 199, 13], "na yol a\u00e7an patojenlerin ba\u015f\u0131nda yer almaktad\u0131r1,2."], [[54.0, 586.0, 336, 11], "P.aeruginosa\u2019n\u0131n neden oldu\u011fu enfeksiyonlar\u0131n kontrol\u00fc, antibiyoti\u011fe diren\u00e7li su\u015flar\u0131n"], [[43.0, 599.0, 352, 11], "ortaya \u00e7\u0131kmas\u0131 nedeni ile g\u00fc\u00e7le\u015fmektedir. Beta-laktamaz \u00fcretimi gibi \u00e7e\u015fitli mekanizmalar"], [[43.0, 628.0, 16, 10], "548"], [[317.0, 628.0, 92, 10], "M\u0130KROB\u0130YOLOJ\u0130 B\u00dcLTEN\u0130"]], [680, 453]], [3, [[[299.0, 44.0, 113, 8], "Erdal B, Yal\u0131nay M, Elmas \u00c7, Yaz\u0131c\u0131 GN."], [[43.0, 72.0, 355, 11], "sonucu, antibiyotiklere kar\u015f\u0131 h\u0131zla diren\u00e7 kazanma yetene\u011fine sahip P.aeruginosa\u2019n\u0131n teda-"], [[43.0, 84.0, 357, 11], "visinde ciddi sorunlarla kar\u015f\u0131la\u015f\u0131lmaktad\u0131r. Ayr\u0131ca artan antibiyotik direnci, hastal\u0131\u011f\u0131n ortaya"], [[43.0, 95.0, 357, 13], "\u00e7\u0131kma oran\u0131n\u0131 ve P.aeruginosa enfeksiyonuna ba\u011fl\u0131 mortaliteyi art\u0131rmaktad\u0131r1,3. Beta-laktam"], [[43.0, 110.0, 359, 11], "grubu bir antibiyotik olan piperasilin, beta-laktamaz inhibit\u00f6r\u00fc olan tazobaktam ile birlikte,"], [[43.0, 123.0, 360, 11], "beta-laktamaz \u00fcreten P.aeruginosa\u2019n\u0131n neden oldu\u011fu a\u011f\u0131r enfeksiyonlar\u0131n tedavisinde kulla-"], [[43.0, 134.0, 355, 13], "n\u0131lmaktad\u0131r4. Ayn\u0131 \u015fekilde siprofloksasin (CIP) de P.aeruginosa\u2019n\u0131n neden oldu\u011fu \u00e7e\u015fitli en-"], [[43.0, 148.0, 354, 11], "feksiyonlar\u0131n tedavisinde yayg\u0131n olarak kullan\u0131lan bir antibiyotiktir. S\u0131k kullan\u0131lmas\u0131na ba\u011fl\u0131"], [[43.0, 159.0, 314, 13], "olarak CIP\u2019ye diren\u00e7li P.aeruginosa izolatlar\u0131n\u0131n oran\u0131 h\u0131zla art\u0131\u015f g\u00f6stermektedir2."], [[54.0, 180.0, 342, 11], "P.aeruginosa\u2019n\u0131n pek \u00e7ok vir\u00fclans fakt\u00f6r\u00fc yan\u0131nda, son y\u0131llarda biyofilm yapma ve quo-"], [[43.0, 192.0, 349, 11], "rum sensing (QS) yetene\u011fi \u00f6nem kazanm\u0131\u015ft\u0131r. Biyofilmler, antimikrobiyal ila\u00e7lara dirence"], [[43.0, 205.0, 356, 11], "neden olmalar\u0131, s\u00fcrekli enfeksiyon kayna\u011f\u0131 olabilmeleri, patojen mikroorganizmalar\u0131 bar\u0131n-"], [[43.0, 218.0, 347, 11], "d\u0131rmalar\u0131, diren\u00e7 plazmitlerinin kar\u015f\u0131l\u0131kl\u0131 olarak ge\u00e7i\u015fine yol a\u00e7malar\u0131 nedeni ile vir\u00fclans\u0131n"], [[43.0, 231.0, 184, 11], "art\u0131\u015f\u0131nda etkin rol oynayan fakt\u00f6rlerden biridir."], [[54.0, 249.0, 332, 11], "P.aeruginosa\u2019da biyofilm olu\u015fumunu da i\u00e7eren bir\u00e7ok vir\u00fclans fakt\u00f6r\u00fc \u00fcretiminin d\u00fc-"], [[43.0, 262.0, 357, 11], "zenlenmesinde QS\u2019nin g\u00f6rev ald\u0131\u011f\u0131 bilinmektedir. Yap\u0131lan \u00e7al\u0131\u015fmalarda, \u00f6zellikle biyofilmin"], [[43.0, 273.0, 359, 13], "yap\u0131lanma, olgunla\u015fma ve da\u011f\u0131lma a\u015famalar\u0131nda QS sisteminin rol\u00fc a\u00e7\u0131k\u00e7a g\u00f6sterilmi\u015ftir5,6."], [[43.0, 288.0, 347, 11], "Gen ekspresyon analizleri ile P.aeruginosa\u2019daki \u00e7ok say\u0131da genin QS sistemleri taraf\u0131ndan"], [[43.0, 301.0, 348, 11], "d\u00fczenlendi\u011fi g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. P.aeruginosa\u2019da las, rhl, PQS ve entegre QS (IQS) olmak \u00fcze-"], [[43.0, 313.0, 340, 11], "re d\u00f6rt tip QS sistemi bulunmaktad\u0131r. Las QS sistemi, sinyal sentaz lasI taraf\u0131ndan N-3-"], [[43.0, 326.0, 338, 11], "oksododekanoil homoserin laktonlar\u0131n\u0131n (N-3-C12-HSL) \u00fcretiminde ve hedef genlerin"], [[43.0, 339.0, 349, 11], "transkripsiyonunu aktive eden sinyalin resept\u00f6r lasR taraf\u0131ndan alg\u0131lanmas\u0131nda rol oynar."], [[43.0, 352.0, 357, 11], "Rhl QS sisteminde rhlI, N butanoil-L-homoserin laktonun (C4-HSL) sentezinde rol oynar ve"], [[43.0, 365.0, 351, 11], "sinyal resept\u00f6r\u00fc olan rhlR, C4-HSL ona ba\u011fland\u0131\u011f\u0131nda hedef gen ekspresyonunu ind\u00fckle-"], [[43.0, 376.0, 41, 13], "mektedir1."], [[54.0, 396.0, 343, 11], "Bu \u00e7al\u0131\u015fmada, P.aeruginosa enfeksiyonlar\u0131n\u0131n tedavisinde kullan\u0131lan piperasilin/tazobak-"], [[43.0, 409.0, 351, 11], "tam (TZP) ve CIP antibiyotiklerinin sub-minimal inhibit\u00f6r konsantrasyonlar\u0131n\u0131n (sub-M\u0130K)"], [[43.0, 421.0, 356, 11], "P.aeruginosa\u2019n\u0131n \u00f6nemli vir\u00fclans fakt\u00f6rlerinden biri olan biyofilm yap\u0131m\u0131 \u00fczerine etkilerinin"], [[43.0, 434.0, 348, 11], "ara\u015ft\u0131r\u0131lmas\u0131 ve bu etkinin, taramal\u0131 elektron mikroskobu (SEM) ile g\u00f6sterilmesi ama\u00e7lan-"], [[43.0, 447.0, 363, 11], "m\u0131\u015ft\u0131r. Ayr\u0131ca biyofilm olu\u015fumu ile ili\u015fkili lasI, lasR, rhlI ve rhlR QS genlerinin varl\u0131\u011f\u0131n\u0131n ara\u015ft\u0131-"], [[43.0, 460.0, 358, 11], "r\u0131lmas\u0131 ve biyofilm yap\u0131m \u015fiddeti ile QS genleri aras\u0131nda ili\u015fki olup olmad\u0131\u011f\u0131n\u0131n g\u00f6sterilmesi"], [[43.0, 473.0, 186, 11], "de \u00e7al\u0131\u015fman\u0131n ikinci amac\u0131 olarak belirlenmi\u015ftir."], [[43.0, 491.0, 82, 11], "GERE\u00c7 ve Y\u00d6NTEM"], [[54.0, 510.0, 69, 11], "Bakteri \u0130zolatlar\u0131"], [[54.0, 528.0, 342, 11], "\u00c7al\u0131\u015fmaya, Gazi \u00dcniversitesi T\u0131p Fak\u00fcltesi T\u0131bbi Mikrobiyoloji Laboratuvar\u0131 k\u00fclt\u00fcr kolek-"], [[43.0, 541.0, 347, 11], "siyonunda yer alan TZP ve CIP\u2019ye duyarl\u0131 (s\u0131ras\u0131yla, n= 15 ve n= 21) ve diren\u00e7li (s\u0131ras\u0131yla,"], [[43.0, 554.0, 346, 11], "n= 9 ve n= 3) olarak saptanan 24 P.aeruginosa izolat\u0131 dahil edildi. \u0130zolatlar \u00f6zel bir hasta"], [[43.0, 566.0, 355, 11], "grubuna ait olmamakla birlikte, balgam (n= 2), endotrakeal aspirat (ETA) (n= 2), idrar (n="], [[43.0, 579.0, 348, 11], "5), yara (n= 6), kan, gaita (n= 9) gibi \u00e7e\u015fitli klinik \u00f6rneklerden izole edildi. Pozitif kontrol"], [[43.0, 592.0, 353, 11], "olarak P.aeruginosa ATCC 27853 su\u015fu kullan\u0131ld\u0131. Bakterilerin tan\u0131mlanmas\u0131, konvansiyonel"], [[43.0, 605.0, 251, 11], "y\u00f6ntemler ve API 20 NE sistemi (BioM\u00e9rieux, Fransa) ile yap\u0131ld\u0131."], [[43.0, 628.0, 92, 10], "M\u0130KROB\u0130YOLOJ\u0130 B\u00dcLTEN\u0130"], [[392.0, 628.0, 16, 10], "549"]], [680, 453]], [4, [[[43.0, 41.0, 254, 8], "Piperasilin/Tazobaktam ve Siprofloksasin Sub-minimal \u0130nhibit\u00f6r Konsantrasyonlar\u0131nda"], [[43.0, 50.0, 271, 8], "Pseudomonas aeruginosa Biyofilm Olu\u015fumunun ve Quorum Sensing Genlerinin Ara\u015ft\u0131r\u0131lmas\u0131"], [[54.0, 72.0, 122, 11], "Antibiyotik Duyarl\u0131l\u0131k Testleri"], [[54.0, 90.0, 344, 11], "\u00c7al\u0131\u015fmaya al\u0131nan P.aeruginosa izolatlar\u0131n\u0131n TZP ve CIP antibiyotik duyarl\u0131l\u0131klar\u0131, Klinik ve"], [[43.0, 103.0, 354, 11], "Laboratuvar Standartlar\u0131 Enstit\u00fcs\u00fc [Clinical Laboratory Standards Institute (CLSI)] \u00f6nerileri"], [[43.0, 116.0, 351, 11], "do\u011frultusunda Kirby-Bauer disk dif\u00fczyon y\u00f6ntemi kullan\u0131larak belirlendi. TZP i\u00e7in inhibis-"], [[43.0, 128.0, 354, 11], "yon zon \u00e7ap\u0131 \u2265 21 mm olan izolatlar duyarl\u0131, \u2264 14 mm olanlar diren\u00e7li; CIP i\u00e7in inhibisyon"], [[43.0, 139.0, 325, 13], "zon \u00e7ap\u0131 \u2265 21 mm olan izolatlar duyarl\u0131, \u2264 15 mm olanlar ise diren\u00e7li kabul edildi7."], [[54.0, 160.0, 144, 11], "M\u0130K ve Sub-M\u0130K\u2019lerin Belirlenmesi"], [[54.0, 178.0, 327, 11], "TZP ve CIP antibiyotiklerinin her bir izolat i\u00e7in M\u0130K de\u011ferleri, CLSI M100 rehberine"], [[43.0, 191.0, 347, 11], "g\u00f6re \u00f6nerilen mikrodil\u00fcsyon y\u00f6ntemi uygulanarak katyon eklenmi\u015f Mueller Hinton buy-"], [[43.0, 202.0, 353, 13], "yon (CAMHB, Fluka, \u0130spanya) besiyeri kullan\u0131larak saptand\u01317. CIP, 128-0.0625 \u03bcg/ml, TZP"], [[43.0, 215.0, 357, 13], "1024-0.5 \u03bcg/ml M\u0130K aral\u0131\u011f\u0131nda \u00e7al\u0131\u015f\u0131ld\u0131. 0.5 McFarland (1.5 x 108 CFU/ml) bulan\u0131kl\u0131k stan-"], [[43.0, 229.0, 347, 11], "dard\u0131ndaki bakteri s\u00fcspansiyonlar\u0131 haz\u0131rlanan plaklara uygun miktarda eklenerek 20 saat"], [[43.0, 242.0, 350, 11], "37\u00b0C\u2019de ink\u00fcbasyon sonunda plaklar hem g\u00f6zle hem de 450 nm\u2019de spektrofotometrede"], [[43.0, 255.0, 353, 11], "(Biotek, ABD) okutuldu. \u00dcremenin g\u00f6r\u00fclmedi\u011fi en d\u00fc\u015f\u00fck antibiyotik konsantrasyonu M\u0130K"], [[43.0, 268.0, 345, 11], "de\u011feri olarak belirlendi. Her izolat\u0131n M\u0130K de\u011ferlerinin 1/2, 1/4 ve 1/8 konsantrasyonlar\u0131"], [[43.0, 281.0, 148, 11], "sub-M\u0130K de\u011ferleri olarak kabul edildi."], [[54.0, 299.0, 157, 11], "Biyofilm Yap\u0131m\u0131n\u0131n De\u011ferlendirilmesi"], [[54.0, 318.0, 348, 11], "Biyofilm yap\u0131m\u0131n\u0131n de\u011ferlendirilmesinde mikrotitrasyon plak y\u00f6ntemi kullan\u0131ld\u0131. %1 glu-"], [[43.0, 330.0, 343, 11], "koz i\u00e7eren Luria Bertani buyyon (LB, Himedia, Hindistan) besiyeri i\u00e7inde 0.5 McFarland"], [[43.0, 343.0, 350, 11], "ayar\u0131nda bulan\u0131kl\u0131k olacak \u015fekilde haz\u0131rlanan bakteri s\u00fcspansiyonlar\u0131ndan e\u015fit miktarlarda"], [[43.0, 356.0, 347, 11], "96 kuyucuklu mikroplak i\u00e7erisine da\u011f\u0131t\u0131ld\u0131. Haz\u0131rlanan her izolat i\u00e7in \u00fc\u00e7 kuyucuk kullan\u0131l-"], [[43.0, 369.0, 352, 11], "d\u0131. Negatif kontrol olarak, bakteri i\u00e7ermeyen %1 glukoz i\u00e7eren LB besiyeri kullan\u0131ld\u0131. Mik-"], [[43.0, 382.0, 354, 11], "roplaklar 37\u00b0C\u2019de 24 saat aerop ortamda ink\u00fcbe edildikten sonra tutunamayan bakterileri"], [[43.0, 394.0, 358, 11], "uzakla\u015ft\u0131rmak i\u00e7in \u00fc\u00e7 kez distile su ile y\u0131kand\u0131. Daha sonra her kuyucu\u011fa %0.1 kristal viyole"], [[43.0, 407.0, 357, 11], "\u00e7\u00f6zeltisinden e\u015fit miktarlarda da\u011f\u0131t\u0131larak 15 dakika oda s\u0131cakl\u0131\u011f\u0131nda ink\u00fcbe edildi. \u0130nk\u00fcbas-"], [[43.0, 420.0, 363, 11], "yon sonunda mikroplaklar distile su ile tekrar \u00fc\u00e7 kez y\u0131kand\u0131 ve kurutuldu. Kuyucuk \u00e7eperine"], [[43.0, 433.0, 365, 11], "tutunan film tabaka, %95\u2019lik etanol ilavesiyle 10 dakika \u00e7\u00f6zd\u00fcr\u00fclerek, 570 nm\u2019de ELISA oku-"], [[43.0, 444.0, 359, 13], "yucu (Biotek, ABD) ile okutuldu8. TZP ve CIP sub-M\u0130K konsantrasyonlar\u0131nda (M\u0130K/2, M\u0130K/4"], [[43.0, 458.0, 352, 11], "ve M\u0130K/8) biyofilm olu\u015fumlar\u0131 da ayn\u0131 y\u00f6ntem ile belirlendi. Sonu\u00e7lar, P.aeruginosa ATCC"], [[43.0, 471.0, 358, 11], "27853 su\u015funun absorbans de\u011ferleri %100 kabul edilerek kar\u015f\u0131la\u015ft\u0131rmal\u0131 olarak yorumland\u0131."], [[54.0, 490.0, 293, 11], "Biyofilm Tabakas\u0131n\u0131n Taramal\u0131 Elektron Mikroskop ile G\u00f6r\u00fcnt\u00fclenmesi"], [[54.0, 506.0, 336, 13], "Her antibiyotik i\u00e7in kuvvetli biyofilm olu\u015fturan birer izolat se\u00e7ildi ve 1.5 x 108 CFU/ml"], [[43.0, 521.0, 348, 11], "bakteri s\u00fcspansiyonlar\u0131 haz\u0131rland\u0131. Yirmi d\u00f6rt kuyucuklu h\u00fccre k\u00fclt\u00fcr plaklar\u0131na yerle\u015ftiri-"], [[43.0, 534.0, 352, 11], "len \u201ccoverslip\u201d (Erie Scientific, Amerika)\u2019lerin \u00fczeri e\u015fit miktarlarda TSB (LAB M, \u0130ngiltere)"], [[43.0, 546.0, 355, 11], "besiyeri ile kapland\u0131. Antibiyotiklerin sub-M\u0130K konsantrasyonlar\u0131ndan ve haz\u0131rlanan bakteri"], [[43.0, 559.0, 347, 11], "s\u00fcspansiyonlar\u0131ndan ilgili kuyucuklara e\u015fit miktarlarda eklendikten sonra plaklar 37\u00b0C\u2019de"], [[43.0, 572.0, 356, 11], "20 saat ink\u00fcbasyona b\u0131rak\u0131ld\u0131. \u0130nk\u00fcbasyon sonunda kuyucuklar \u00fc\u00e7 kez distile su ile y\u0131kand\u0131."], [[43.0, 585.0, 350, 11], "Sub-M\u0130K konsantrasyonlarda olu\u015fan biyofilm tabakalar\u0131n\u0131 incelemek \u00fczere \u201ccoverslip\u201dler,"], [[43.0, 598.0, 359, 11], "kritik nokta kurutma cihaz\u0131nda (Leica EM CPD030, Avusturya) kurutulduktan sonra al\u00fcmin-"], [[43.0, 610.0, 353, 11], "yum ta\u015f\u0131ma haznelerine s\u0131v\u0131 g\u00fcm\u00fc\u015f ile yap\u0131\u015ft\u0131r\u0131ld\u0131 ve kaplama cihaz\u0131nda (Denton vacuum,"], [[43.0, 628.0, 16, 10], "550"], [[317.0, 628.0, 92, 10], "M\u0130KROB\u0130YOLOJ\u0130 B\u00dcLTEN\u0130"]], [680, 453]], [5, [[[299.0, 44.0, 113, 8], "Erdal B, Yal\u0131nay M, Elmas \u00c7, Yaz\u0131c\u0131 GN."], [[43.0, 72.0, 357, 11], "LLC Desk V sputter/etch unit, Amerika) alt\u0131n-paladyum (AuPd) ile kapland\u0131. Taramal\u0131 elekt-"], [[43.0, 84.0, 293, 11], "ron mikroskobunda (Zeiss EVO LS 10, Almanya) incelenerek foto\u011frafland\u0131."], [[54.0, 103.0, 67, 11], "DNA \u0130zolasyonu"], [[54.0, 121.0, 338, 11], "Biyofilm \u00f6zellikleri belirlenmi\u015f 24 izolat\u0131n QS genleri (lasI, lasR, rhlI ve rhlR), polimeraz"], [[43.0, 134.0, 358, 11], "zincir reaksiyonu (PCR) y\u00f6ntemi ile kromozomal DNA\u2019n\u0131n amplifikasyonu yap\u0131larak saptan-"], [[43.0, 147.0, 353, 11], "d\u0131. Bu y\u00f6ntemde, DNA eldesi i\u00e7in ekstraksiyon kiti (Invitek GmbH, Berlin) ile \u00fcretici firma-"], [[43.0, 160.0, 355, 11], "n\u0131n \u00f6nerileri do\u011frultusunda tasarlanm\u0131\u015f DNA ekstraksiyon protokol\u00fc kullan\u0131ld\u0131. Elde edilen"], [[43.0, 173.0, 348, 11], "DNA \u00f6rnekleri Nanodrop ND-1000 spektrofotometre cihaz\u0131 (Thermo Scientific, ABD) ile"], [[43.0, 185.0, 345, 11], "\u00f6l\u00e7\u00fcld\u00fc. \u00d6rnekler kullan\u0131lana kadar -20\u02daC\u2019de sakland\u0131. QS mekanizmas\u0131nda rol alan lasI,"], [[43.0, 196.0, 319, 13], "lasR, rhlI ve rhlR genleri i\u00e7in Tablo I\u2019de verilen oligon\u00fckleotit primerler kullan\u0131ld\u01319."], [[54.0, 217.0, 193, 11], "\u201cQuorum Sensing\u201d Genlerinin Amplifikasyonu"], [[54.0, 235.0, 334, 17], "5 \u03bcl 10 x amplifikasyon tampon \u00e7\u00f6zeltisi, 3 \u03bcl MgCl2 (25 mM), 5 \u03bcl dNTP kar\u0131\u015f\u0131m\u0131 (2"], [[43.0, 248.0, 348, 11], "mM), 0.26 \u03bcl Taq DNA polimeraz (5 U) (Bioron, Almanya), her bir primerden 0.6 \u03bcl (50"], [[43.0, 261.0, 355, 11], "pmol), 32.54 \u03bcl distile su ve 3 \u03bcl DNA i\u00e7eren amplifikasyon reaksiyonlar\u0131 toplam hacim 50"], [[43.0, 273.0, 350, 11], "\u03bcl olacak \u015fekilde haz\u0131rland\u0131. \u00d6rneklerin amplifikasyonlar\u0131; termal d\u00f6ng\u00fc cihaz\u0131nda (Gene-"], [[43.0, 286.0, 355, 11], "Amp PCR System 9700, Applied Biosystems, ABD) \u00f6n denat\u00fcrasyon i\u00e7in 94\u00b0C\u2019de 5 dakika"], [[43.0, 299.0, 347, 11], "ve 34 d\u00f6ng\u00fc 94\u00b0C\u2019de 30 saniye denat\u00fcrasyon, 50\u00b0C\u2019de 30 saniye ba\u011flanma, 72\u00b0C\u2019de 2"], [[43.0, 312.0, 359, 11], "dakika uzama sonras\u0131 ard\u0131ndan 72\u00b0C\u2019de 10 dakika ek uzama a\u015famas\u0131 olacak \u015fekilde ger\u00e7ek-"], [[43.0, 325.0, 356, 11], "le\u015ftirildi. \u0130stisna olarak rhlR geni i\u00e7in primer ba\u011flanma a\u015famas\u0131, 52\u00b0C\u2019de 30 saniye \u015feklinde"], [[43.0, 337.0, 42, 11], "uyguland\u0131."], [[54.0, 356.0, 345, 11], "Amplifikasyon \u00fcr\u00fcnlerinin bant b\u00fcy\u00fckl\u00fckleri; lasI geni: 605 baz \u00e7ifti (bp), lasR geni: 725"], [[43.0, 369.0, 351, 11], "bp, rhlI geni: 625 bp, rhlR geni: 730 bp \u015feklinde tespit edildi\u011finde gen pozitifli\u011fi saptan-"], [[43.0, 382.0, 351, 11], "d\u0131. Agaroz elektroforez s\u0131ras\u0131nda PCR ile pozitif kontrol olarak \u00e7al\u0131\u015f\u0131lan P.aeruginosa ATCC"], [[43.0, 394.0, 359, 11], "27853 su\u015fu ve DNA molek\u00fcler a\u011f\u0131rl\u0131k belirteci (Seegene, Kore) kullan\u0131larak jel g\u00f6r\u00fcnt\u00fcleme"], [[43.0, 405.0, 264, 13], "sistemi (Syngene, Ingenius, ABD) ile PCR \u00fcr\u00fcnleri g\u00f6r\u00fcnt\u00fclendi9,10."], [[54.0, 426.0, 75, 11], "\u0130statistiksel Analiz"], [[54.0, 442.0, 335, 13], "Verilerin istatistiksel analizinde, IBM SPSS\u00ae 15 (Statistical Package for Social Sciences)"], [[43.0, 457.0, 353, 11], "program\u0131 kullan\u0131ld\u0131. Genel verilerinin de\u011ferlendirilmesinde ve biyofilm yap\u0131m\u0131 ile QS gen-"], [[43.0, 470.0, 350, 11], "lerinin kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131nda ki-kare testi, antimikrobiyallerin biyofilm olu\u015fumuna etkilerinin"], [[43.0, 482.0, 346, 11], "de\u011ferlendirilmesinde ise Friedman varyans analizi ve Bonferroni d\u00fczeltmeli Wilcoxon W"], [[43.0, 495.0, 306, 11], "analiz testleri kullan\u0131ld\u0131. p\u2264 0.05 de\u011feri istatistiksel olarak anlaml\u0131 kabul edildi."], [[49.0, 525.0, 235, 10], "Tablo I. \u201cQuorum Sensing\u201d Gen Amplikonlar\u0131 \u0130\u00e7in Kullan\u0131lan Primerler"], [[49.0, 540.0, 76, 10], "Gen Forward Primer"], [[231.0, 540.0, 56, 10], "Reverse Primer"], [[49.0, 554.0, 297, 10], "lasI 5\u2019-ATG ATC GTA CAA ATT GGT CGG C-3\u2019 5\u2019-GTC ATG AAA CCG CCA GTC G-3\u2019"], [[49.0, 567.0, 147, 10], "lasR 5\u2019-ATG GCC TTG GTT GAC GGT T-3\u2019"], [[231.0, 567.0, 172, 10], "5\u2019-GCA AGA TCA GAG AGT AAT AAG ACC CA-3\u2019"], [[49.0, 581.0, 296, 10], "rhlI 5\u2019-CTT GGT CAT GAT CGA ATT GCT C-3\u2019 5\u2019-ACG GCT GAC GAC CTC ACA C-3\u2019"], [[49.0, 594.0, 292, 10], "rhlR 5\u2019-CAA TGA GGA ATG ACG GAG GC-3\u2019 5\u2019-GCT TCA GAT GAG GCC CAG C-3\u2019"], [[43.0, 628.0, 92, 10], "M\u0130KROB\u0130YOLOJ\u0130 B\u00dcLTEN\u0130"], [[392.0, 628.0, 16, 10], "551"]], [680, 453]], [6, [[[43.0, 41.0, 254, 8], "Piperasilin/Tazobaktam ve Siprofloksasin Sub-minimal \u0130nhibit\u00f6r Konsantrasyonlar\u0131nda"], [[43.0, 50.0, 271, 8], "Pseudomonas aeruginosa Biyofilm Olu\u015fumunun ve Quorum Sensing Genlerinin Ara\u015ft\u0131r\u0131lmas\u0131"], [[43.0, 72.0, 46, 11], "BULGULAR"], [[54.0, 90.0, 352, 11], "P.aeruginosa izolatlar\u0131, balgam (n= 2), ETA (n= 2), idrar (n= 5), yara (n= 6) ve kan, biyop-"], [[43.0, 103.0, 349, 11], "si, gaita vb. \u00e7e\u015fitli klinik \u00f6rneklerden (n= 9) elde edilmi\u015ftir. \u0130zolatlar\u0131n 21\u2019i CIP\u2019ye duyarl\u0131,"], [[43.0, 115.0, 257, 11], "\u00fc\u00e7\u00fc diren\u00e7li ve 15\u2019i TZP\u2019ye duyarl\u0131, dokuzu diren\u00e7li bulunmu\u015ftur."], [[54.0, 134.0, 339, 11], "\u0130zolatlar\u0131n be\u015finin zay\u0131f, alt\u0131s\u0131n\u0131n orta kuvvetli, 13\u2019\u00fcn\u00fcn kuvvetli biyofilm olu\u015fturduklar\u0131"], [[43.0, 146.0, 361, 11], "saptanm\u0131\u015ft\u0131r. Di\u011fer klinik \u00f6rneklerden farkl\u0131 olarak balgam (n= 2) ve ETA (n= 2) \u00f6rneklerinin"], [[43.0, 159.0, 355, 11], "tamam\u0131n\u0131n ATCC 27853\u2019ten kuvvetli biyofilm olu\u015fturdu\u011fu saptanm\u0131\u015ft\u0131r. Biyofilm olu\u015fumu"], [[43.0, 172.0, 350, 11], "ve \u00f6rneklerin izole edildi\u011fi b\u00f6lgeler kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda aradaki fark anlams\u0131z bulunmu\u015ftur"], [[43.0, 184.0, 45, 11], "(p= 0.166)."], [[54.0, 203.0, 344, 11], "\u0130zolatlar\u0131n biyofilm \u00f6l\u00e7\u00fcmleriyle diren\u00e7 durumlar\u0131 kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, aradaki fark istatis-"], [[43.0, 215.0, 351, 17], "tiksel olarak anlaml\u0131 bulunmam\u0131\u015ft\u0131r (pCIP= 0.731; pTZP= 0.104). P.aeruginosa ATCC 27853"], [[43.0, 228.0, 356, 11], "su\u015funa oranla zay\u0131f biyofilm olu\u015fturan be\u015f izolat\u0131n tamam\u0131n\u0131n TZP\u2019ye, d\u00f6rd\u00fcn\u00fcn ise CIP\u2019ye"], [[43.0, 241.0, 150, 11], "duyarl\u0131 oldu\u011fu saptanm\u0131\u015ft\u0131r (Tablo II)."], [[54.0, 259.0, 330, 11], "P.aeruginosa izolatlar\u0131n\u0131n M\u0130K de\u011ferleri, CIP i\u00e7in 0.125-32 \u03bcg/ml, TZP i\u00e7in ise 2-256"], [[43.0, 272.0, 350, 11], "\u03bcg/ml aral\u0131\u011f\u0131nda saptanm\u0131\u015ft\u0131r. Zay\u0131f biyofilm olu\u015fturan be\u015f izolat\u0131n her iki antibiyotik i\u00e7in"], [[43.0, 284.0, 357, 11], "M\u0130K de\u011ferlerine bak\u0131ld\u0131\u011f\u0131nda kuvvetli biyofilm olu\u015fturan izolatlar\u0131n M\u0130K de\u011ferlerine k\u0131yasla"], [[43.0, 297.0, 353, 11], "daha d\u00fc\u015f\u00fck oldu\u011fu bulunmu\u015ftur. T\u00fcm izolatlar i\u00e7in bulunan absorbans de\u011ferlerinin orta-"], [[43.0, 310.0, 354, 11], "lamas\u0131na bak\u0131ld\u0131\u011f\u0131nda, CIP\u2019nin M\u0130K/2 konsantrasyonda, kontrol olarak kullan\u0131lan antibiyo-"], [[43.0, 322.0, 352, 11], "tiksiz kuyucu\u011fun %18.2\u2019si; M\u0130K/4 konsantrasyonda %25.2\u2019si; M\u0130K/8 konsantrasyonda ise"], [[43.0, 335.0, 347, 11], "%26.8\u2019i kadar absorbans verdi\u011fi saptanm\u0131\u015ft\u0131r. TZP antibiyoti\u011finin ise M\u0130K/2 konsantras-"], [[43.0, 348.0, 351, 11], "yonda kontrol\u00fcn %15.2\u2019si; M\u0130K/4 konsantrasyonda %19.4\u2019\u00fc; M\u0130K/8 konsantrasyonda ise"], [[43.0, 360.0, 355, 11], "%25\u2019i kadar absorbans verdi\u011fi bulunmu\u015ftur. \u00c7al\u0131\u015fma sonucunda, iki antibiyoti\u011fin de sub-"], [[43.0, 373.0, 347, 11], "M\u0130K konsantrasyonlar\u0131nda, antibiyotiksiz durum ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, biyofilm yap\u0131m\u0131n\u0131"], [[43.0, 386.0, 341, 11], "doz ba\u011f\u0131ml\u0131 olarak azaltt\u0131\u011f\u0131 ve en fazla biyofilm olu\u015fumunun azald\u0131\u011f\u0131 konsantrasyonun"], [[43.0, 398.0, 121, 11], "M\u0130K/2 oldu\u011fu tespit edilmi\u015ftir."], [[54.0, 417.0, 338, 11], "Her iki antibiyoti\u011fin M\u0130K/2, M\u0130K/4, M\u0130K/8 konsantrasyonlar\u0131nda biyofilm geli\u015fimi \u00fcze-"], [[43.0, 429.0, 346, 11], "rine etkileri kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, aradaki fark istatistiksel olarak anlaml\u0131 bulunmam\u0131\u015ft\u0131r (p>"], [[43.0, 442.0, 24, 11], "0.05)."], [[54.0, 460.0, 346, 11], "Biyofilm yap\u0131m\u0131n\u0131n en fazla antibiyotiklerin M\u0130K/2 konsantrasyonlar\u0131nda azald\u0131\u011f\u0131 sonucu"], [[43.0, 473.0, 223, 11], "SEM g\u00f6r\u00fcnt\u00fclerine bak\u0131larak do\u011frulanm\u0131\u015ft\u0131r (Resim 1,2)."], [[49.0, 500.0, 329, 10], "Tablo II. Biyofilm \u015eiddeti ile Siprofloksasin ve Piperasilin/Tazobaktam Duyarl\u0131l\u0131klar\u0131 Aras\u0131ndaki \u0130li\u015fki"], [[168.0, 515.0, 52, 10], "Siprofloksasin"], [[293.0, 515.0, 88, 10], "Piperasilin/Tazobaktam"], [[49.0, 529.0, 65, 10], "Biyofilm olu\u015fumu"], [[141.0, 529.0, 8, 10], "*R"], [[189.0, 529.0, 9, 10], "*D"], [[228.0, 529.0, 28, 10], "Toplam"], [[286.0, 529.0, 8, 10], "*R"], [[333.0, 529.0, 9, 10], "*D"], [[370.0, 529.0, 28, 10], "Toplam"], [[49.0, 542.0, 40, 10], "Kuvvetli (n)"], [[143.0, 542.0, 5, 10], "1"], [[189.0, 542.0, 9, 10], "12"], [[237.0, 542.0, 9, 10], "13"], [[288.0, 542.0, 5, 10], "7"], [[336.0, 542.0, 5, 10], "6"], [[380.0, 542.0, 9, 10], "13"], [[49.0, 556.0, 58, 10], "Orta kuvvetli (n)"], [[143.0, 556.0, 5, 10], "1"], [[191.0, 556.0, 5, 10], "5"], [[240.0, 556.0, 5, 10], "6"], [[288.0, 556.0, 5, 10], "2"], [[336.0, 556.0, 5, 10], "4"], [[382.0, 556.0, 5, 10], "6"], [[49.0, 569.0, 30, 10], "Zay\u0131f (n)"], [[143.0, 569.0, 5, 10], "1"], [[191.0, 569.0, 5, 10], "4"], [[240.0, 569.0, 5, 10], "5"], [[288.0, 569.0, 5, 10], "0"], [[336.0, 569.0, 5, 10], "5"], [[382.0, 569.0, 5, 10], "5"], [[49.0, 583.0, 39, 10], "Toplam (n)"], [[143.0, 583.0, 5, 10], "3"], [[189.0, 583.0, 9, 10], "21"], [[237.0, 583.0, 9, 10], "24"], [[288.0, 583.0, 5, 10], "9"], [[333.0, 583.0, 9, 10], "15"], [[380.0, 583.0, 9, 10], "24"], [[50.0, 596.0, 75, 8], "*R: Diren\u00e7li, *D: Duyarl\u0131."], [[43.0, 628.0, 16, 10], "552"], [[317.0, 628.0, 92, 10], "M\u0130KROB\u0130YOLOJ\u0130 B\u00dcLTEN\u0130"]], [680, 453]], [7, [[[299.0, 44.0, 113, 8], "Erdal B, Yal\u0131nay M, Elmas \u00c7, Yaz\u0131c\u0131 GN."], [[49.0, 73.0, 5, 10], "A"], [[143.0, 74.0, 5, 10], "B"], [[235.0, 73.0, 5, 10], "C"], [[330.0, 73.0, 6, 10], "D"], [[43.0, 176.0, 363, 10], "Resim 1. A. Antibiyotiksiz ortamda ve B. Piperasilin/tazobaktam M\u0130K/8, C. M\u0130K/4, D. MiK/2 konsantrasyon-"], [[43.0, 186.0, 195, 10], "lar\u0131nda P.aeruginosa biyofilm tabakas\u0131n\u0131n SEM g\u00f6r\u00fcnt\u00fcs\u00fc."], [[48.0, 206.0, 5, 10], "A"], [[137.0, 206.0, 5, 10], "B"], [[234.0, 208.0, 5, 10], "C"], [[325.0, 208.0, 6, 10], "D"], [[44.0, 318.0, 350, 10], "Resim 2. A. Antibiyotiksiz ortamda ve B. Siprofloksasin M\u0130K/8, C. M\u0130K/4 D. MiK/2 konsantrasyonlar\u0131nda"], [[44.0, 328.0, 169, 10], "P.aeruginosa biyofilm tabakas\u0131n\u0131n SEM g\u00f6r\u00fcnt\u00fcs\u00fc."], [[53.0, 346.0, 344, 11], "\u00c7al\u0131\u015fmada incelenen 24 izolat\u0131n 23\u2019\u00fcnde; lasI (605 bp) ve lasR (725 bp) genlerini belir-"], [[42.0, 359.0, 356, 11], "ten amplifikasyon \u00fcr\u00fcn\u00fc saptan\u0131rken, bir izolatta lasI ve lasR gen amplifikasyon \u00fcr\u00fcn\u00fc sap-"], [[42.0, 372.0, 357, 11], "tanmam\u0131\u015ft\u0131r. LasI ve lasR genleri negatif olan izolat\u0131n, yara yerinden izole edilen ayn\u0131 izolat"], [[42.0, 384.0, 360, 11], "oldu\u011fu g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. \u00c7al\u0131\u015fmada incelenen 24 izolat\u0131n hepsinde rhlI geni (625 bp), 13\u2019\u00fcnde"], [[42.0, 397.0, 361, 11], "rhlR geni (730 bp) saptanm\u0131\u015f, 11 izolatta ise rhlR geni saptanmam\u0131\u015ft\u0131r. Baz\u0131 izolatlar\u0131n amp-"], [[42.0, 410.0, 226, 11], "lifikasyon \u00fcr\u00fcnlerinin g\u00f6r\u00fcnt\u00fcs\u00fc Resim 3\u2019te g\u00f6sterilmi\u015ftir."], [[53.0, 433.0, 104, 7], "M 1 2 3 4 5 6 7 8 9 10 11 12 NK PK M"], [[240.0, 431.0, 104, 7], "M 1 2 3 4 5 6 7 8 9 10 11 12 NK PK M"], [[205.0, 464.0, 15, 6], "605 b\u00e7"], [[388.0, 456.0, 15, 6], "725 b\u00e7"], [[44.0, 499.0, 5, 10], "A"], [[58.0, 516.0, 104, 7], "M 1 2 3 4 5 6 7 8 9 10 11 12 NK PK M"], [[231.0, 498.0, 5, 10], "B"], [[245.0, 516.0, 104, 7], "M 1 2 3 4 5 6 7 8 9 10 11 12 NK PK M"], [[203.0, 547.0, 15, 6], "625 b\u00e7"], [[387.0, 546.0, 15, 6], "730 b\u00e7"], [[44.0, 584.0, 5, 10], "C"], [[231.0, 584.0, 6, 10], "D"], [[43.0, 599.0, 227, 10], "Resim 3. A. lasI I, B. lasR, C. rhlI ve D. rhlR genlerinin jel g\u00f6r\u00fcnt\u00fcs\u00fc."], [[43.0, 608.0, 278, 10], "M: Molek\u00fcler a\u011f\u0131rl\u0131k standard\u0131, PK: P.aeruginosa ATCC 27853 NK: Negatif kontrol."], [[43.0, 628.0, 92, 10], "M\u0130KROB\u0130YOLOJ\u0130 B\u00dcLTEN\u0130"], [[392.0, 628.0, 16, 10], "553"]], [680, 453]], [8, [[[43.0, 41.0, 254, 8], "Piperasilin/Tazobaktam ve Siprofloksasin Sub-minimal \u0130nhibit\u00f6r Konsantrasyonlar\u0131nda"], [[43.0, 50.0, 271, 8], "Pseudomonas aeruginosa Biyofilm Olu\u015fumunun ve Quorum Sensing Genlerinin Ara\u015ft\u0131r\u0131lmas\u0131"], [[49.0, 78.0, 267, 10], "Tablo III. \u201cQuorum Sensing\u201d Gen Varl\u0131\u011f\u0131n\u0131n Biyofilm D\u00fczeylerine G\u00f6re Da\u011f\u0131l\u0131m\u0131"], [[171.0, 93.0, 12, 10], "lasI"], [[236.0, 93.0, 15, 10], "lasR"], [[304.0, 93.0, 12, 10], "rhlI"], [[367.0, 93.0, 15, 10], "rhlR"], [[49.0, 106.0, 71, 10], "Kuvvetli biyofilm (n)"], [[172.0, 106.0, 9, 10], "13"], [[239.0, 106.0, 9, 10], "13"], [[305.0, 106.0, 9, 10], "13"], [[372.0, 106.0, 5, 10], "6"], [[49.0, 120.0, 89, 10], "Orta kuvvetli biyofilm (n)"], [[175.0, 120.0, 5, 10], "6"], [[241.0, 120.0, 5, 10], "6"], [[307.0, 120.0, 5, 10], "6"], [[372.0, 120.0, 5, 10], "4"], [[49.0, 133.0, 61, 10], "Zay\u0131f biyofilm (n)"], [[175.0, 133.0, 5, 10], "4"], [[241.0, 133.0, 5, 10], "4"], [[307.0, 133.0, 5, 10], "5"], [[372.0, 133.0, 5, 10], "3"], [[49.0, 147.0, 39, 10], "Toplam (n)"], [[172.0, 147.0, 9, 10], "23"], [[239.0, 147.0, 9, 10], "23"], [[305.0, 147.0, 9, 10], "24"], [[370.0, 147.0, 9, 10], "13"], [[53.0, 185.0, 338, 11], "QS gen varl\u0131\u011f\u0131n\u0131n biyofilm d\u00fczeylerine g\u00f6re da\u011f\u0131l\u0131m\u0131 Tablo III\u2019te verilmi\u015ftir. Zay\u0131f, orta"], [[42.0, 197.0, 353, 11], "kuvvetli ve kuvvetli biyofilm olu\u015fturan izolatlar aras\u0131nda QS gen varl\u0131\u011f\u0131 a\u00e7\u0131s\u0131ndan istatistik-"], [[42.0, 210.0, 204, 11], "sel olarak anlaml\u0131 bir fark saptanmam\u0131\u015ft\u0131r (p> 0.05)."], [[42.0, 229.0, 45, 11], "TARTI\u015eMA"], [[53.0, 247.0, 342, 11], "P.aeruginosa enfeksiyonlar\u0131n\u0131n patogenezinde biyofilm olu\u015fumunun \u00f6nemli rol oynad\u0131-"], [[42.0, 260.0, 350, 11], "\u011f\u0131 bilinmektedir. Biyofilm enfeksiyonlar\u0131n\u0131n artmas\u0131 ile birlikte biyofilm direncini ayd\u0131nlat-"], [[42.0, 271.0, 212, 13], "maya y\u00f6nelik yap\u0131lan \u00e7al\u0131\u015fmalar \u00f6nem kazanm\u0131\u015ft\u0131r6,11."], [[53.0, 292.0, 326, 11], "2018 y\u0131l\u0131nda yap\u0131lan bir \u00e7al\u0131\u015fmada, 40 P.aeruginosa klinik izolat\u0131n\u0131n %42.5\u2019inin (n="], [[42.0, 305.0, 339, 11], "17) zay\u0131f biyofilm, %27.5\u2019inin (n= 11) orta kuvvetli biyofilm, %7.5\u2019inin (n= 3) kuvvetli"], [[42.0, 316.0, 352, 13], "biyofilm olu\u015fturdu\u011fu, ancak, %22.5\u2019inin (n= 9) biyofilm olu\u015fturmad\u0131\u011f\u0131 tespit edilmi\u015ftir12."], [[42.0, 331.0, 349, 11], "Ayn\u0131 ara\u015ft\u0131rmac\u0131lar\u0131n, ventilat\u00f6r ili\u015fkili pn\u00f6moni hastalar\u0131n\u0131n ETA (n= 19) ve bronkoalveo-"], [[42.0, 344.0, 353, 11], "ler lavaj (n= 1) \u00f6rneklerinden izole edilen toplam 20 klinik P.aeruginosa izolat\u0131n\u0131n biyofilm"], [[42.0, 357.0, 347, 11], "\u00fcretimini kalitatif ve kantitatif olmak \u00fczere iki farkl\u0131 y\u00f6ntem kullanarak de\u011ferlendirdikleri"], [[42.0, 370.0, 351, 11], "ba\u015fka bir \u00e7al\u0131\u015fmada, kantitatif y\u00f6ntem ile izolatlar\u0131n %75\u2019inin biyofilm olu\u015fturdu\u011fu (%25"], [[42.0, 383.0, 347, 11], "biyofilm olu\u015fturmayan, %40 zay\u0131f, %25 orta ve %10 kuvvetli biyofilm olu\u015fturan) bulun-"], [[42.0, 394.0, 340, 13], "mu\u015ftur13. Bu \u00e7al\u0131\u015fmada; klinik \u00f6rneklerden izole edilen P.aeruginosa izolatlar\u0131n\u0131n tama-"], [[42.0, 409.0, 343, 11], "m\u0131n\u0131n (n= 24) biyofilm \u00fcretme yetene\u011finde oldu\u011fu, ancak biyofilm \u00fcretim oranlar\u0131nda"], [[42.0, 422.0, 354, 11], "literat\u00fcrdeki di\u011fer \u00e7al\u0131\u015fmalarda oldu\u011fu gibi farkl\u0131l\u0131klar g\u00f6r\u00fcld\u00fc\u011f\u00fc tespit edilmi\u015ftir. Kuvvetli"], [[42.0, 435.0, 349, 11], "biyofilm \u00fcretiminin en fazla oldu\u011fu grubun, solunum yolu \u00f6rnekleri olan ETA ve balgam"], [[42.0, 448.0, 348, 11], "\u00f6rnekleri oldu\u011fu g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. Bu sonu\u00e7, P.aeruginosa izolatlar\u0131n\u0131n kuvvetli biyofilm yap-"], [[42.0, 461.0, 351, 11], "ma yeteneklerinin ciddi solunum yolu enfeksiyonlar\u0131na yol a\u00e7mas\u0131na zemin haz\u0131rlayan bir"], [[42.0, 474.0, 165, 11], "fakt\u00f6r olabilece\u011fi fikrini desteklemektedir."], [[53.0, 493.0, 333, 11], "P.aeruginosa enfeksiyonlar\u0131n\u0131n tedavisinde kullan\u0131lan CIP ve beta-laktamaz inhibit\u00f6r\u00fc"], [[42.0, 506.0, 334, 11], "bir antibiyotik olan TZP direnciyle ilgili literat\u00fcrde \u00e7ok say\u0131da yay\u0131na rastlamak m\u00fcm-"], [[42.0, 517.0, 342, 13], "k\u00fcnd\u00fcr14-16. Bu \u00e7al\u0131\u015fmalara bak\u0131ld\u0131\u011f\u0131nda, P.aeruginosa izolatlar\u0131n\u0131n diren\u00e7 paternlerinin,"], [[42.0, 532.0, 342, 11], "\u00e7al\u0131\u015fman\u0131n yap\u0131ld\u0131\u011f\u0131 y\u0131l, b\u00f6lge ve hastaneye g\u00f6re de\u011fi\u015fkenlik g\u00f6sterdi\u011fi g\u00f6r\u00fclmektedir."], [[42.0, 545.0, 340, 11], "Bu \u00e7al\u0131\u015fmaya dahil edilen izolatlar\u0131n \u00fc\u00e7\u00fcn\u00fcn CIP\u2019ye diren\u00e7li, 21\u2019inin duyarl\u0131; TZP\u2019ye ise"], [[42.0, 558.0, 339, 11], "dokuzunun diren\u00e7li, 15\u2019inin duyarl\u0131 oldu\u011fu bulunmu\u015ftur. TZP\u2019nin diren\u00e7 oran\u0131, CIP\u2019ye"], [[42.0, 571.0, 142, 11], "k\u0131yasla daha y\u00fcksek tespit edilmi\u015ftir."], [[43.0, 628.0, 16, 10], "554"], [[317.0, 628.0, 92, 10], "M\u0130KROB\u0130YOLOJ\u0130 B\u00dcLTEN\u0130"]], [680, 453]], [9, [[[299.0, 44.0, 113, 8], "Erdal B, Yal\u0131nay M, Elmas \u00c7, Yaz\u0131c\u0131 GN."], [[53.0, 71.0, 344, 11], "Solunum yolu enfeksiyonlar\u0131, d\u00fcnya \u00e7ap\u0131nda yayg\u0131n morbidite ve mortalite nedenlerin-"], [[42.0, 84.0, 349, 11], "dendir. \u00d6zellikle alt solunum yolu enfeksiyonu olan hastalardan izole edilen P.aeruginosa"], [[42.0, 95.0, 229, 13], "izolatlar\u0131nda \u00e7oklu antibiyotik direncine rastlanmaktad\u0131r17."], [[53.0, 115.0, 339, 11], "\u00dclkemizde yap\u0131lan bir \u00e7al\u0131\u015fmada, P.aeruginosa izolatlar\u0131n\u0131n antibiyotik duyarl\u0131l\u0131klar\u0131 de-"], [[42.0, 128.0, 343, 11], "\u011ferlendirilmi\u015f; yara (n= 38) ve idrar (n= 36) \u00f6rneklerinden izole edilen izolatlara k\u0131yasla"], [[42.0, 141.0, 341, 11], "solunum sistemi izolatlar\u0131nda (n= 52) TZP diren\u00e7 oran\u0131n\u0131n daha y\u00fcksek oldu\u011fu (n= 33,"], [[42.0, 154.0, 340, 11], "%63), CIP diren\u00e7 oran\u0131n\u0131n ise yara izolatlar\u0131nda (n= 19, %50) daha y\u00fcksek oldu\u011fu (n="], [[42.0, 165.0, 101, 13], "30, %58) bulunmu\u015ftur18."], [[53.0, 186.0, 336, 11], "Gram-negatif bakterilerdeki antimikrobiyal diren\u00e7 ile biyofilm olu\u015fumu aras\u0131ndaki ili\u015f-"], [[42.0, 199.0, 336, 11], "kinin ara\u015ft\u0131r\u0131ld\u0131\u011f\u0131 bir \u00e7al\u0131\u015fmada, balgam ve ETA gibi solunum yolu \u00f6rneklerinden izole"], [[42.0, 212.0, 337, 11], "edilen P.aeruginosa izolatlar\u0131n\u0131n, kan ve idrar \u00f6rneklerinden izole edilenlere g\u00f6re daha"], [[42.0, 225.0, 346, 11], "fazla biyofilm olu\u015fturdu\u011fu ve bu izolatlar\u0131n TZP ve CIP gibi antimikrobiyal ajanlara daha"], [[42.0, 238.0, 340, 11], "diren\u00e7li olduklar\u0131, biyofilm yap\u0131m\u0131 ile CIP direnci aras\u0131nda istatistiksel olarak anlaml\u0131 bir"], [[42.0, 249.0, 339, 13], "ili\u015fki oldu\u011fu tespit edilmi\u015ftir (p= 0.041)19. Bu \u00e7al\u0131\u015fmada, alt solunum yolu \u00f6rne\u011fi olan"], [[42.0, 264.0, 337, 11], "ETA \u00f6rneklerinden izole edilen iki izolat\u0131n da kuvvetli biyofilm yapt\u0131\u011f\u0131 ve bu izolatlar\u0131n"], [[42.0, 277.0, 336, 11], "TZP\u2019ye diren\u00e7li olduklar\u0131 saptanm\u0131\u015ft\u0131r. Bu sonu\u00e7, alt solunum yollar\u0131nda kolonize olan"], [[42.0, 290.0, 341, 11], "P.aeruginosa\u2019n\u0131n tedavisi g\u00fc\u00e7, a\u011f\u0131r klinik tablolara neden olabilece\u011fini bir kez daha d\u00fc-"], [[42.0, 303.0, 353, 11], "\u015f\u00fcnd\u00fcrmektedir. Ayr\u0131ca \u00e7al\u0131\u015fmada, bakterilerin biyofilm yapma yeteneklerinin azalmas\u0131 ile"], [[42.0, 316.0, 344, 11], "antimikrobiyallere olan duyarl\u0131l\u0131klar\u0131nda art\u0131\u015f olabilece\u011fini destekleyen bir sonu\u00e7 olarak,"], [[42.0, 329.0, 337, 11], "P.aeruginosa ATCC 27853\u2019e oranla daha az biyofilm olu\u015fturan be\u015f izolat\u0131n tamam\u0131n\u0131n"], [[42.0, 342.0, 226, 11], "TZP\u2019ye, d\u00f6rd\u00fcn\u00fcn ise CIP\u2019ye duyarl\u0131 oldu\u011fu saptanm\u0131\u015ft\u0131r."], [[53.0, 361.0, 330, 11], "Disk dif\u00fczyon y\u00f6nteminin, sadece serbest bakterilerin diren\u00e7 profilini yans\u0131tmas\u0131 ne-"], [[42.0, 374.0, 335, 11], "deni ile bu \u00e7al\u0131\u015fmada, biyofilm olu\u015fumunun antibiyotik direncine olan ger\u00e7ek etkisini"], [[42.0, 387.0, 347, 11], "anlayabilmek i\u00e7in kullan\u0131lan antibiyotiklerin sub-M\u0130K dozlarda biyofilm yap\u0131m\u0131n\u0131 nas\u0131l et-"], [[42.0, 400.0, 84, 11], "kiledi\u011fi ara\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r."], [[53.0, 418.0, 328, 11], "Antibiyotiklerin sub-M\u0130K\u2019lerinin enfeksiyona kar\u015f\u0131 konak\u00e7\u0131 savunmas\u0131na yard\u0131m ede-"], [[42.0, 431.0, 350, 11], "cek antimikrobiyal etkiyi sa\u011flayabildi\u011fi bildirilmi\u015ftir. Bu konsantrasyonlar\u0131n, bakteri h\u00fccre"], [[42.0, 444.0, 346, 11], "duvar\u0131nda de\u011fi\u015fiklik, mikrobiyal aderansta ve biyofilm yap\u0131m\u0131nda azalma, fagositer akti-"], [[42.0, 457.0, 343, 11], "vitenin art\u0131\u015f\u0131, mikrobiyal toksinlerin sal\u0131n\u0131m\u0131n\u0131n azalmas\u0131 gibi etkiler yaparak mikroorga-"], [[42.0, 469.0, 177, 13], "nizmalar \u00fczerine etki ettikleri g\u00f6sterilmi\u015ftir20."], [[53.0, 489.0, 350, 11], "P.aeruginosa\u2019ya kar\u015f\u0131 y\u00fcksek bakterisidal aktiviteye ve terap\u00f6tik etkinli\u011fe sahip oldu\u011fu bi-"], [[42.0, 502.0, 360, 11], "linen CIP, bir\u00e7ok gram-negatif patojene kar\u015f\u0131 tercih edilen bir ila\u00e7t\u0131r. P.aeruginosa\u2019n\u0131n PAO1"], [[42.0, 515.0, 348, 11], "standart su\u015fu ve d\u00f6rt klinik izolat\u0131n dahil edildi\u011fi Hindistan\u2019da yap\u0131lan bir \u00e7al\u0131\u015fmada, CIP"], [[42.0, 528.0, 348, 11], "sub-M\u0130K konsantrasyonunun (M\u0130K/4) P.aeruginosa kayma, y\u00fczme ve titreme hareketleri-"], [[42.0, 541.0, 351, 11], "ni, proteaz, elastaz, ramnolipid, aljinat ve siderofor gibi vir\u00fclans fakt\u00f6rlerinin \u00fcretimini ve"], [[42.0, 552.0, 276, 13], "biyofilm yap\u0131m\u0131n\u0131 anlaml\u0131 derecede azaltt\u0131\u011f\u0131 g\u00f6sterilmi\u015ftir (p< 0.05)21."], [[53.0, 573.0, 343, 11], "Literat\u00fcrde say\u0131l\u0131 \u00e7al\u0131\u015fmalardan olan bir grup ara\u015ft\u0131rmac\u0131n\u0131n yapm\u0131\u015f oldu\u011fu bir \u00e7al\u0131\u015fma-"], [[42.0, 586.0, 343, 11], "da; TZP sub-M\u0130K\u2019lerinin (M\u0130K/2), P.aeruginosa fenotipine ve fizyolojik \u00f6zelliklerine ba\u011fl\u0131"], [[42.0, 599.0, 339, 11], "hareketini, morfolojik \u00f6zelliklerini de\u011fi\u015ftirdi\u011fi ve biyofilm yap\u0131m\u0131n\u0131 azaltt\u0131\u011f\u0131 bulunmu\u015f-"], [[43.0, 628.0, 92, 10], "M\u0130KROB\u0130YOLOJ\u0130 B\u00dcLTEN\u0130"], [[392.0, 628.0, 16, 10], "555"]], [680, 453]]]